Background: Endometriosis is a polygenic and multifactorial disease. DNA damage plays a major role in mutagenesis, carcinogenesis and aging and is usually repaired by the action of several DNA repair enzymes. We investigated the association of the common variations of the DNA repair genes XRCC1 and XRCC4 with susceptibility to endometriosis in an Iranian population. Methods: In total, 160 patients with endometriosis (stages I-IV) and 174 healthy women were included in this case-control study. Genotyping of XRCC1 codon 399 as well as of XRCC4 -1394T/G, codon 247 and intron 3 insertion/deletion variations was performed using restriction fragment length polymorphism analysis of PCR-amplified fragments. Results: The XRCC4 -1394TG genotype frequency was significantly lower (p = 0.005) in the patients (9.4%) than in the controls (21.1%). The frequency of the -1394G allele was significantly lower (p < 0.0001) in the patients (6.6%) than in the controls (19.0%). There were no statistically significant differences in the genotype and allele frequencies of the XRCC1 codon 399, XRCC4 codon 247 and XRCC4 intron 3 insertion/deletion polymorphisms between the cases and controls. Conclusions: The XRCC4 -1394T/G polymorphism was associated with susceptibility to endometriosis in an Iranian population.

Acién P, Velasco I: Endometriosis: a disease that remains enigmatic. ISRN Obstet Gynecol 2013;2013:242149.
Rahmioglu N, Nyholt DR, Morris AP, Missmer SA, Montgomery GW, Zondervan KT: Genetic variants underlying risk of endometriosis: insights from meta-analysis of eight genome-wide association and replication datasets. Hum Reprod Update 2014;20:702-716.
Hsieh YY, Chang CC, Chen SY, Chen CP, Lin WH, Tsai FJ: XRCC1 399 Arg-related genotype and allele, but not XRCC1 His107Arg, XRCC1 Trp194Arg, KCNQ2, AT1R, and hOGG1 polymorphisms, are associated with higher susceptibility of endometriosis. Gynecol Endocrinol 2012;28:305-309.
Bau DT, Hsieh YY, Wan L, Wang RF, Liao CC, Lee CC, Lin CC, Tsai CH, Tsai FJ: Polymorphism of XRCC1 codon Arg399Gln is associated with higher susceptibility to endometriosis. Chin J Physiol 2007;50:326-329.
Hsieh YY, Bau DT, Chang CC, Tsai CH, Chen CP, Tsai FJ: XRCC4 codon 247*A and XRCC4 promoter -1394*T related genotypes but not XRCC4 intron 3 gene polymorphism are associated with higher susceptibility for endometriosis. Mol Reprod Dev 2008;75:946-951.
Agic A, Djalali S, Diedrich K, Hornung D: Apoptosis in endometriosis. Gynecol Obstet Invest 2009;68:217-223.
Lin ZH, Chen JC, Wang YS, Huang TJ, Wang J, Long XD: DNA repair gene XRCC4 codon 247 polymorphism modified diffusely infiltrating astrocytoma risk and prognosis. Int J Mol Sci 2013;15:250-260.
Radhakrishnan SK, Jette N, Lees-Miller SP: Non-homologous end joining: emerging themes and unanswered questions. DNA Repair 2014;17:2-8.
Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril 1997;67:817-821.
Zondervan KT, Cardon LR, Kennedy SH: What makes a good case-control study? Design issues for complex traits such as endometriosis. Hum Reprod 2002;17:1415-1423.
Attar R, Cacina C, Sozen S, Attar E, Agachan B: DNA repair genes in endometriosis. Genet Mol Res 2010;9:629-636.
Altmae S, Esteban FJ, Stavreus-Evers A, Simon C, Giudice L, Lessey BA, Horcajadas JA, Macklon NS, D'Hooghe T, Campoy C, Fauser BC, Salamonsen LA, Salumets A: Guidelines for the design, analysis and interpretation of ‘omics' data: focus on human endometrium. Hum Reprod Update 2013;20:12-28.
Sundqvist J, Xu H, Vodolazkaia A, Fassbender A, Kyama C, Bokor A, Gemzell-Danielsson K, D'Hooghe TM, Falconer H: Replication of endometriosis-associated single-nucleotide polymorphisms from genome-wide association studies in a Caucasian population. Hum Reprod 2013;28:835-839.
Guo SW: Association of endometriosis risk and genetic polymorphisms involving sex steroid biosynthesis and their receptors: a meta-analysis. Gynecol Obstet Invest 2006;61:90-105.
Cardon LR, Bell JI: Association study designs for complex diseases. Nat Rev Genet 2001;2:91-99.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.